MA Research Update — September 17, 2026 (Updated)
Updated Thesis
Mastercard operates the world's second-largest open-loop payment network, enabling authorization, clearing and settlement across the MasterCard, Maestro and Cirrus brands while layering on value-added services in cyber and intelligence, data analytics, open banking and digital identity for roughly 39,800 employees serving consumers, merchants, issuers and governments globally. The business quality is exceptional on fundamentals: TTM gross margin is 100%, TTM operating margin is 59.8%, TTM net margin is 46.3% and ROE is 232.5%, with revenue up 14.1% and earnings up 18.6% in the most recent quarter, and free cash flow of $18.65 per share on $40.00 of revenue per share. The shares at $567.65 trade at 30.8x trailing earnings, 14.19x sales, 30.44x free cash flow and 23.11x EV/EBITDA, a premium absolute multiple set that sits in a cheap regime relative to its own five-year history, and the stock is undervalued versus the $696 blended fair value estimate, implying 22.6% upside and matching a Strong Buy consensus with a $696 average target.
The investment grade as of this refresh is A- — high business quality. A-tier business, B-tier valuation with 22.6% upside to $696 fair value.
Key Metrics at a Glance
- Revenue growth: +14.1% year over year
- Net margin: 46.3%
- Fair value upside: +22.6% to our estimate of $696
Current price: $567.65
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. Mastercard Incorporated remains in our covered universe with a high-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full MA research →](/stocks/MA)